Oncolytics Biotech, Inc. (USA) (NASDAQ:ONCY)

This biotech could change the face of cancer worldwide.

ONCY is a long term hold of mine - 12 years.
It is not over until the fat lady sings, but the fat lady is smiling today. Do your own research - the ONCY web site is very informative. Also check out the TED talk by Patrick Lee on the web. The MF recently (aprox.three days ago) published a rather uniformed article on this stock. Enough said.

Oncolytics is a development-stage biotech company. It's single product under development is Reolysin, a virus that has been demonstrated to selectively reproduce in cancer cells with an activated RAS pathway. Around 1/3 of primary tumors and 2/3 of metastatic tumors have an activate RAS pathway, so there is a considerable market for this drug should it eventually win approval from the FDA.

The company has an impressive collection of ongoing and completed clinical trials. Furthermore, the National Cancer Institute (NCI) in the USA and the National Cancer Institute of Canada (NCIC) have been sufficiently impressed that they are conducting research at their expense on the company's behalf. The external funding for these studies is roughy $45M, a number that can't be sneezed at given that ONCY currently has a market cap of $250M. The NCIC has announced that it will conduct randomized controlled trials in breast, Lung, colorectal, and prostate cancer. The NCI is conducting trials in multiple myeloma, pancreatic, and ovarian cancer. A successful result in any one of these indications would more than justify the current market valuation.

Furthermore, the company is currently involved in a phase III trial for head and neck cancer. Time will only tell what the result of this trial will be, but all previous results have been quite positive.

The company is currently oversold, as of August 2012, with roughly 45-days worth of trading volume worth of short interest. Should the phase 3 head and neck trial report positive results the shorts will be in real trouble trying to cover their positions with so much short interest.

There is not much more to say, but for everyone's health we should all wish for a positive outcome. It is worth mentioning that roughly 1/2 of men and 1/3 of women will develop cancer in their lifetimes. With 7B people in the world, this company has the potential to be a true benefit to mankind.

I believe the PHIII trial has a high likelihood of success, in which case the stock will take off given the high number of cancer indications reosylin is applicable to

The Reolysin product appears to actually work, isn't very toxic, has a novel mechanism of action, and is synergistic with other cancer chemotherapy treatments. I expect it to become a standard component of most chemotherapy regimens. Also, once Reolysin gets approved, the real strength of this company will become evident: they have developed unique expertise in this drug class that will give them an advantage over those in big pharma who decide to play catchup. It seems likely that a company like Abbott or Lilly would scoop them up.

Clinical trials show control of cancer in 65-75% of patients and control of 95% of metastatic cancers. Reolysin has only trivial side effects. Check www.clinicaltrials.gov REOLYSIN for current clinical trials sponsored by NCI, UK, Univ. of Texas and others. Solid patent protection in place, including coverage for manufacturing process.

Have been following for several months. These guys are on to something

Oncolytics is a speculative play, no doubt. No completed Ph3 yet. It has one drug. A small cap with little cash. So why buy. Simple. Risk reward.

ONCY is trying to cure cancer, as are many. What differentiates it, is it's one drug's mechanism of action, if proven successful, will work against many common cancer indications. That gives it a big revenue potential relative to current market cap. The side effect profile is minimal and generally well understood. The virus itself is well known scientifically and generally benign in humans. The drug (a virus) has proven in early trials to be capable of dramatic outcomes. Since it works synergistically with chemotherapy, trials are easy to design and set up. Give standard of care and standard of care plus Reosylin. If it is proven to work in one indication, stock price will appreciate significantly from current levels. Given that there are many indications entering trials recently, with gov't and health institute support, those in the research community must see some possibility of success. So if you are willing to invest in what are very risky biotech companies, this company is not a bad choice, as they are focussed on one thing, Reosylin, that if successful, could used in conjunction with standard of care across many different cancers.

Something like 64% of drugs that reach this level are eventually approved. Looking at the size of the ongoing PIII that is expected to be only 280 patients is interesting. The smallness is a real in your face we can show the FDA statically significance in just 280 patients. However ONCY management is saying they really expect statically significance numbers at just 80 patients and only need the other 200 for a more complete safety package even when the normal side effects are simple flu like, lookout chemo.

Future financing looks to be put off till sometime next year. Recent comments by the company CEO they have several options available and are being looked at. With only about year + of cash on hand and delayed financing it appears the company believes upcoming PII results will worth the wait. Still I can not completely discount some sort of small bridge financing or forced warrant conversion should the PPS reach $6.50 US prior to ASCO 2011. ONCY is something to be watched closely in the coming months.

Numerous phase 3 trials underway. They were unable to complete a phase 2 because patients "lived too long". April press release indicates they can "cure" cancer in mice. Looks and photographs of recent results from post presentation speaks for itself. This will be a ten dollar stock as trials near completion and 20 plus with the results.

They have a solid product in Resolyn and in stage 3
in 2 trials.A patnership should be forthcoming shortly

Oncy appears to be well managed, the research is solid, and there are a core group of individuals who believe in ultimate success. Key investors believe enough to back their beleif with dollars. Large drug companies are watching close with keen interest. A successful product will cause a stamped of offers to buy and the stock to soar. The risk is reasonable and the price is right. I'll invest and wait 5 years. sf

Dr. Brad Thompson, President and CEO said last week "Oncolytics is the first company to reach an agreement with the FDA on a Phase 3 trial design for an intravenously-administered oncolytic virus under the SPA process," Now I’m not a scientist but that sounds like a major accomplishment to me. A positive outcome could lead to a license application for REOLYSIN, which is the Company’s potential cancer therapeutic. Needless to say the profit potential for a successful treatment would be enormous.

The stock has many trials in progress for its only product "Reolysin". Its very close to approval of a phase III FDA trial. A conference call on it phase III is scheduled for 8:30 am EDT tomorrow. After hours up 30%. Its one of the few times you will see a stock with so much potential so cheap.

It's very difficult to get to stage 2. Within the next 6 months to a year this drug will be in stage 3. At that point this stock will take off. Likely it'll be bought out by a big name drug company.

Oversold PHII biotech with proprietary replication competent virual oncolytic therapy with excellent first in class potential

This company has a cancer treatment in phase II trials that has practically no side effects other than mild flu-like symptoms that subside within a day. The product is made from a common virus that destroys cancer cells but does not harm normal cells. Phase I trials in both systemic delivery and in combination with radiation have shown it to be safe. No maximum dose has been found. It works on a pathway that is common in many cancers. It has shown evidence that it could be effective against metastatic cancers. The company has plenty of cash on hand. Progress is slow but Biotech Monthly covers the stock and has expressed optimism at their chace for success..

This company has tremendous potential. Take a close look at this one.

I hate to go so against the grain on this one and be the only bear, but its stock looks like it is heading lower to me. They just don't have anything that they can commercialize soon enough. Nothing in Phase III yet and they losing $10 million a year. They do not have the cash to make it long enough to get anything approved and the lower their shares go, the less likely they are to be able to issue more shares. Their best hope is that their science does turn out to be as promising as they hope and they can sell it off or sell the company off before it goes under.